Journal Article

DKFZ-2026-00631

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Introducing Key Performance Metrics for Assessing the Benefits and Harm of the Prostate Cancer Diagnostic Pathway.

Padhani, A. R. ; Carlsson, S.DKFZ* ; Bratt, O. ; Schoots, I. G.

2026
Elsevier Amsterdam

Abstract: Traditional accuracy metrics no longer suffice for comparing diagnostic pathways for prostate cancer; new comparative performance metrics are needed that prioritize the overall benefit-to-harm ratio. Key performance metrics, such as biopsy efficiency, biopsy (grade) selectivity, and biopsy avoidance safety, enable meaningful patient-level comparisons across studies. Standardized benefit-to-harm metrics reporting enhances quality assurance, informs personalized diagnostics, and supports integration into clinical guidelines to improve the safety of prostate cancer diagnosis.

Keyword(s): Biopsy ; Endpoints ; Magnetic resonance imaging ; Outcome measures ; Prostate cancer

Note: Brief Report / epub

---

Contributing Institute(s):

1. C070 Klinische Epidemiologie der Krebsfrüherkennung (C070)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2026

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---